scholarly journals Role of antihypertensive drugs in the treatment of migraine

2015 ◽  
Vol 156 (5) ◽  
pp. 179-185 ◽  
Author(s):  
Gergely Fehér ◽  
Gabriella Pusch
Keyword(s):  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Channel Blockers ◽  
Migraine Prevention ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

The treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specific drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specific drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Orv. Hetil., 2015, 156(5), 179–185.

scholarly journals Tata Laksana Non Imunosupresan Sindrom Nefrotik pada Anak

Sari Pediatri ◽  
2017 ◽  
Vol 19 (1) ◽  
pp. 53
Author(s):  
Sudung Oloan Pardede
Keyword(s):  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Channel Blockers ◽  
Angiotensin Receptor ◽  
Recommended Daily Allowance ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers ◽  
Daily Allowance

Sindrom nefrotik adalah keadaan klinis yang terdiri atas proteinuria masif, hipo­albuminemia (< 2,5 g/dL), edema, dan hiperkolesterolemia. Terapi utama sindrom nefrotik adalah imunosupresan terutama kortikosteroid. Pada sindrom nefrotik relaps sering atau dependen steroid, dan sindrom nefrotik resisten steroid, selain steroid diberikan juga imunosupresan lain seperti siklofosfamid, siklosporin, mikofenolat mofetil, takrolimus, atau pun levamisol. Selain pemberian imunosupresan diperlukan terapi suportif, yang meliputi terapi diitetik,  tata laksana edema, hipertensi, hipovolemia, trombosis, hiperlipidemia, dan infeksi. Tata laksana diitetik terdiri atas kalori yang adekuat, protein sesuai recommended daily allowance, lemak low saturated, dan rendah garam. Komposisi zat gizi yang dianjurkan terdiri atas 10-14% protein; 40-50% lemak poly- dan monounsaturated, 40-50% karbohidrat. Tata laksana  edema terdiri atas restriksi cairan, pemberian diuretik, dan infus albumin jika perlu. Infeksi yang sering terjadi pada sindrom nefrotik adalah selulitis peritonitis, dan pneumonia yang diterapi dengan antibiotik sefotaksim, seftriakson, ko-amoksiklav. Antihipertensi yang digunakan pada anak umumnya diuretik, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, (amblodipin, nifedipin, isradipin), alpha-symphatetic agents, beta blockers dan vasodilator. Aktivitas fisik tidak perlu dibatasi, dan pada edema ringan atau tidak berat tidak perlu dilarang pergi ke sekolah

scholarly journals Combined RAAS and NEP Inhibition

2019 ◽  
Vol 17 ◽  
Author(s):  
Giuseppe Vergaro ◽  
Marco Metra
Keyword(s):  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Receptor ◽  
Mineralocorticoid Receptor Antagonists ◽  
Converting Enzyme Inhibitors ◽  
Drug Classes ◽  
Receptor Blockers ◽  
Nep Inhibition

The neurohormonal model of HF has provided the rationale for the use of drug classes blocking the effectors of both the RAAS and SNS at different sites, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and beta-blockers. Combined NEP and ACE blockade although unsuccessful with omapatrilat in the OVERTURE trial, found success with sacubitril/valsartan in the Paradigm-HF trial. The results of PARADIGM-HF trial represent one of the most significant breakthroughs in the management of HF of the last decade, representing a shift from neurohomonal antagonism to neurohormonal modulation.

Sign in / Sign up

Export Citation Format

Share Document